Literature DB >> 12505638

An improved method for recovering rabies virus from cloned cDNA.

Ken ichi Inoue1, Youko Shoji, Ichiro Kurane, Toshio Iijima, Takeo Sakai, Kinjiro Morimoto.   

Abstract

A new system for recovery of rabies virus from cDNA plasmid, the transcription of which was driven by cellular RNA polymerase II, was developed. The plasmid contains full-length viral cDNA flanked by hammerhead ribozyme and hepatitis delta ribozyme sequences, arranged downstream of the cytomegalovirus (CMV) promotor. Transfection with the full-length cDNA plasmid together with helper plasmids encoding viral N, P, and L proteins without supply of T7 RNA polymerase produced a recombinant rabies virus in several cell lines. The efficiency of recovery between the conventional T7 promotor system and the new CMV promotor system was compared using these plasmid constructs. The newly established system is applicable to various cell lines and allows rapid and efficient generation of recombinant rabies virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12505638     DOI: 10.1016/s0166-0934(02)00249-5

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  52 in total

1.  Molecular basis of neurovirulence of flury rabies virus vaccine strains: importance of the polymerase and the glycoprotein R333Q mutation.

Authors:  Lihong Tao; Jinying Ge; Xijun Wang; Hongyue Zhai; Tao Hua; Bolin Zhao; Dongni Kong; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Using rabies virus vaccine strain SRV9 as viral vector to express exogenous gene.

Authors:  Hualei Wang; Hongli Jin; Na Feng; Xuexing Zheng; Ling Li; Yinglin Qi; Meng Liang; Yongkun Zhao; Tiecheng Wang; Yuwei Gao; Changchun Tu; Ningyi Jin; Songtao Yang; Xianzhu Xia
Journal:  Virus Genes       Date:  2015-02-28       Impact factor: 2.332

3.  Rift valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system.

Authors:  Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Production of glycoprotein-deleted rabies viruses for monosynaptic tracing and high-level gene expression in neurons.

Authors:  Ian R Wickersham; Heather A Sullivan; H Sebastian Seung
Journal:  Nat Protoc       Date:  2010-03-04       Impact factor: 13.491

5.  Reverse genetics of rabies virus: new strategies to attenuate virus virulence for vaccine development.

Authors:  Shimao Zhu; Hui Li; Chunhua Wang; Farui Luo; Caiping Guo
Journal:  J Neurovirol       Date:  2015-05-21       Impact factor: 2.643

6.  Gene order rearrangement of the M gene in the rabies virus leads to slower replication.

Authors:  Xian-Feng Yang; Jiao-Jiao Peng; Hong-Ru Liang; You-Tian Yang; Yi-Fei Wang; Xiao-Wei Wu; Jiao-Jiao Pan; Yong-Wen Luo; Xiao-Feng Guo
Journal:  Virusdisease       Date:  2014-06-07

7.  An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.

Authors:  Emily V Nelson; Jennifer R Pacheco; Adam J Hume; Tessa N Cressey; Laure R Deflubé; John B Ruedas; John H Connor; Hideki Ebihara; Elke Mühlberger
Journal:  Antiviral Res       Date:  2017-08-12       Impact factor: 5.970

8.  Rescue of a wild-type rabies virus from cloned cDNA and assessment of the proliferative capacity of recombinant viruses.

Authors:  Qin Tian; Yifei Wang; Qiong Zhang; Jun Luo; Mingzhu Mei; Yongwen Luo; Xiaofeng Guo
Journal:  Virus Genes       Date:  2017-04-26       Impact factor: 2.332

9.  RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication.

Authors:  Arnold Martin; Peter Staeheli; Urs Schneider
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

10.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.